Gemcitabine Plus Nanoparticle Albumin-bound Paclitaxel Versus FOLFIRINOX for Recurrent Pancreatic Cancer After Resection

Hiroki Taguchi; Taiga Otsuka; Mototsugu Shimokawa; Shiho Arima; Shinichi Hashimoto; Akio Ido; Futa Koga; Yujiro Ueda; Junichi Nakazawa; Azusa Komori; Satoshi Otsu; Masaru Fukahori; Akitaka Makiyama; Takuya Honda; Taro Shibuki; Toshihiko Mizuta; Kenji Mitsugi; Kenta Nio; Yasushi Ide; Norio Ureshino; Tsuyoshi Shirakawa

doi:10.21873/anticanres.15145

Gemcitabine Plus Nanoparticle Albumin-bound Paclitaxel Versus FOLFIRINOX for Recurrent Pancreatic Cancer After Resection

Anticancer Res. 2021 Jul;41(7):3573-3582. doi: 10.21873/anticanres.15145.

Authors

Hiroki Taguchi^{1

2}, Taiga Otsuka^{3

4}, Mototsugu Shimokawa^{5

6}, Shiho Arima⁷, Shinichi Hashimoto⁷, Akio Ido⁷, Futa Koga⁸, Yujiro Ueda⁹, Junichi Nakazawa¹⁰, Azusa Komori¹¹, Satoshi Otsu¹¹, Masaru Fukahori¹², Akitaka Makiyama^{13

14}, Takuya Honda¹⁵, Taro Shibuki^{16

17}, Toshihiko Mizuta^{16

18}, Kenji Mitsugi¹⁹, Kenta Nio²⁰, Yasushi Ide²¹, Norio Ureshino^{22

23}, Tsuyoshi Shirakawa^{24

25}

Affiliations

¹ Department of Gastroenterology, Saiseikai Sendai Hospital, Kagoshima, Japan.
² Department of Gastroenterology, Izumi General Medical Center, Kagoshima, Japan.
³ Department of Medical Oncology, Saga Medical Center Koseikan, Saga, Japan; otsuka-t@umin.ac.jp.
⁴ Department of Internal Medicine, Minato Medical Clinic, Fukuoka, Japan.
⁵ Clinical Research Institute, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan.
⁶ Department of Biostatistics, Yamaguchi University Graduate School of Medicine, Yamaguchi, Japan.
⁷ Digestive and Lifestyle Diseases, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan.
⁸ Department of Hepatobiliary and Pancreatology, Saga Medical Center Koseikan, Saga, Japan.
⁹ Department of Hematology and Oncology, Japanese Red Cross Kumamoto Hospital, Kumamoto, Japan.
¹⁰ Department of Medical Oncology, Kagoshima City Hospital, Kagoshima, Japan.
¹¹ Department of Medical Oncology and Hematology, Oita University Faculty of Medicine, Oita, Japan.
¹² Department of Internal Medicine, Division of Gastroenterology, Kurume University Hospital, Fukuoka, Japan.
¹³ Department of Hematology/Oncology, Japan Community Healthcare Organization Kyushu Hospital, Fukuoka, Japan.
¹⁴ Cancer Center, Gifu University Hospital, Gifu, Japan.
¹⁵ Department of Gastroenterology and Hepatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
¹⁶ Department of Internal Medicine, Imari Arita Kyoritsu Hospital, Saga, Japan.
¹⁷ Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East, Chiba, Japan.
¹⁸ Department of Internal Medicine, Fujikawa Hospital, Saga, Japan.
¹⁹ Department of Medical Oncology, Hamanomachi Hospital, Fukuoka, Japan.
²⁰ Department of Medical Oncology, Sasebo Kyosai Hospital, Nagasaki, Japan.
²¹ Department of Internal Medicine, Karatsu Red Cross Hospital, Saga, Japan.
²² Department of Medical Oncology, Saga Medical Center Koseikan, Saga, Japan.
²³ Department of Medical Oncology, Kimitsu Chuo Hospital, Chiba, Japan.
²⁴ Department of Medical Oncology, Fukuoka Wajiro Hospital, Fukuoka, Japan.
²⁵ Karatsu Higashi-Matsuura Medical Association Center, Saga, Japan.

PMID: 34230153
DOI: 10.21873/anticanres.15145

Abstract

Background/aim: The aim of the study was to evaluate gemcitabine plus nanoparticle albumin-bound paclitaxel (GnP) and FOLFIRINOX for recurrent pancreatic cancer (rPC) after resection.

Patients and methods: Forty-four patients with rPC and 211 with de novo metastatic pancreatic cancer (mPC) who received GnP or FOLFIRINOX as first-line chemotherapy were retrospectively analyzed.

Results: On crude analysis, the median overall survival (OS) was significantly longer in the rPC group than in the mPC group (14.0 vs. 10.6 months, respectively; p=0.02). However, the difference was not significant on adjusted analysis using the Cox proportional hazards model (adjusted p=0.90). Patients receiving FOLFIRINOX (n=10) and GnP (n=34) in the rPC group had comparable OS (medians, 12.2 vs. 14.4 months, respectively; p=0.82) even after adjusting for covariates using the Cox model (adjusted p=0.18).

Conclusion: The outcomes of patients in the rPC and mPC groups were comparable following chemotherapy. Both FOLFIRINOX and GnP may be reasonable options for treating rPC.

Keywords: FOLFIRINOX (FFX); gemcitabine plus nanoparticle albumin–bound paclitaxel (GnP); recurrent pancreatic cancer after resection.

MeSH terms

Adult
Aged
Aged, 80 and over
Albumins / therapeutic use*
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Deoxycytidine / analogs & derivatives*
Deoxycytidine / therapeutic use
Female
Fluorouracil / therapeutic use
Gemcitabine
Humans
Irinotecan / therapeutic use
Leucovorin / therapeutic use
Male
Middle Aged
Nanoparticles / chemistry*
Oxaliplatin / therapeutic use
Paclitaxel / therapeutic use*
Pancreatic Neoplasms / drug therapy*
Retrospective Studies

Substances

130-nm albumin-bound paclitaxel
Albumins
folfirinox
Oxaliplatin
Deoxycytidine
Irinotecan
Paclitaxel
Leucovorin
Fluorouracil
Gemcitabine